SynthesisIntensive care medicine2012
Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis.
Synthesis in Intensive care medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 7 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- The effects and safety of vasopressin receptor agonists in patients with septic shock: a meta-analysis and trial sequential analysis.Critical care (London, England) · 2019Pooled it
- Terlipressin Versus Norepinephrine for Septic Shock: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2019Pooled it
- [S3 guidelines on intensive medical care of cardiac surgery patients : Hemodynamic monitoring and cardiovascular system-an update].Der Anaesthesist · 2018Guideline
- Role of vasopressin and terlipressin in refractory shock compared to conventional therapy in the neonatal and pediatric population: a systematic review, meta-analysis, and trial sequential analysis.Critical care (London, England) · 2017Pooled it
- Scandinavian SSAI clinical practice guideline on choice of first-line vasopressor for patients with acute circulatory failure.Acta anaesthesiologica Scandinavica · 2016Pooled it
- Pooled it
- Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials.Critical care (London, England) · 2012Pooled it
- Protocol for a randomised controlled trial of VAsopressin versus Noradrenaline as Initial therapy in Septic sHock (VANISH).BMJ open · 2014Trial
- Trial
- Vasopressin Initiation Timing and In-Hospital Mortality in Septic Shock: An Observational Study of Large Public Databases.Critical care explorations · 2025Observational
- Vasopressin as adjunctive therapy in pulmonary hypertension associated with refractory systemic hypotension in term newborns.Journal of perinatology : official journal of the California Perinatal Association · 2024Observational
- Management of Sepsis and Septic Shock: What Have We Learned in the Last Two Decades?Microorganisms · 2023Review
- Methylene blue: a controversial diagnostic acid and medication?Toxicology research · 2022Review
- Advances in Vasodilatory Shock: A Concise Review.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2019Review
- Peroxynitrite decomposition catalyst reduces vasopressin requirement in ovine MRSA sepsis.Intensive care medicine experimental · 2019Article
- Shock - Classification and Pathophysiological Principles of Therapeutics.Current cardiology reviews · 2019Review
- Terlipressin for septic shock patients: a meta-analysis of randomized controlled study.Journal of intensive care · 2019Article
- Sepsis: A Review of Advances in Management.Advances in therapy · 2017Review
- Role of vasopressin in current anesthetic practice.Korean journal of anesthesiology · 2017Review
- Safety and Efficacy of Terlipressin in Pediatric Distributive Shock: A Retrospective Analysis in 20 Children.Paediatric drugs · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine the benefits and risks of vasopressin or its analog terlipressin for patients with vasodilatory shock. DATA SOURCE: We searched the CENTRAL, MEDLINE, EMBASE, and LILACS databases (up to March 2011) as well as reference lists of articles and proceedings of major meetings; we also contacted trial authors. We considered randomized and quasirandomized trials of vasopressin or terlipressin versus placebo or supportive treatment in adult and pediatric patients with vasodilatory shock. The primary outcome for this review was short-term all-cause mortality. STUDY SELECTION: We identified 10 randomized trials (1,134 patients). Six studies were considered for the main analysis on mortality in adults. DATA EXTRACTION AND SYNTHESIS: The crude short-term mortality was 206 of 512 (40.2%) in vasopressin/terlipressin-treated patients and 198 of 461 (42.9%) in controls [six trials, risk ratio (RR) = 0.91; 95% confidence interval (CI) 0.79-1.05; P = 0.21; I(2) = 0%]. There were 49 of 463 (10.6%) patients with serious adverse events in the vasopressin/terlipressin arm and 51 of 431 (11.8%) in the control arm (four trials, RR = 0.90; 95% CI 0.49-1.67; P = 0.75; I(2) = 26%). Metaregression analysis showed negative correlation between vasopressin dose and norepinephrine dose (P = 0.03).
conclusionsOverall, use of vasopressin or terlipressin did not produce any survival benefit in the short term in patients with vasodilatory shock. Physicians may value the sparing effects of vasopressin/terlipressin on norepinephrine requirement given its apparent safe profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.